RenovoRx Inc

RNXT | $1.23 0.82% 0.81% 20K

(0.0% 1d) (-20.4% 1m) (-60.9% 1y) (0.0% 2d) (-1.7% 3d) (1.7% 7d) (174.89% volume)
Earnings Calendar: 2024-02-29
Market Cap: $ 20,745,149
https://www.renovorx.com
Sec Filling | Patents | 2021 employees

RenovoRx, a biopharmaceutical company headquartered in Silicon Valley, California, has developed a therapy platform targeting difficult-to-treat tumors. Targeted therapy via the proprietary RenovoRx Trans-Arterial Micro-Perfusion (RenovoTAMP) platform safely and without transmission to non-targeted areas, is the primary focus. RenovoRx's patent portfolio includes seven U.S. patents for its technology. The Company also has secured two separate Orphan Drug Designations from the FDA for intra-arterial gemcitabine including pancreatic cancer and bile duct cancer. The RenovoTAMP therapy is being studied in the Phase III TIGeR-PaC trial for the treatment of locally advanced pancreatic cancer. RenovoRx won the Drug Delivery Technology category of the Fierce Innovation Awards – Life Sciences Edition 2020 for its RenovoTAMP technology.

treatment cancer urea security pancreatic

add to watch list Paper trade email alert is off

Press-releases

RenovoRx Highlights Recent Presentation of Clinical Data Abstract at the 2024 Society of Interventional Radiology Annual Scientific Meeting
Published: 2024-04-17 (Crawled : 23:00) - renovorx.com
RNXT | $1.23 0.82% 0.81% 20K

| Email alert Add to watchlist
presentation meeting

RenovoRx Highlights Recent Presentation of Clinical Data Abstract at the 2024 Society of Interventional Radiology Annual Scientific Meeting
Published: 2024-04-16 (Crawled : 14:00) - biospace.com/
RNXT | $1.23 0.82% 0.81% 20K

| 1.74% | O: -0.87% H: 7.89% C: -0.9%
presentation meeting

RenovoRx Closes $11.1 Million Private Placement, Providing Cash Runway into 2026
Published: 2024-04-15 (Crawled : 14:00) - biospace.com/
RNXT | $1.23 0.82% 0.81% 20K

| -4.1% | O: 4.92% H: 0.0% C: -10.16%
million

RenovoRx Announces $11.1 Million at Market Private Placement
Published: 2024-04-08 (Crawled : 15:00) - biospace.com/
RNXT | $1.23 0.82% 0.81% 20K

| 0.0% | O: -1.71% H: 34.78% C: 1.74%
million market

RenovoRx to Present at the Canaccord Genuity Horizons in Oncology Virtual Conference on April 15, 2024
Published: 2024-04-05 (Crawled : 14:30) - biospace.com/
RNXT | $1.23 0.82% 0.81% 20K

| -2.5% | O: -0.83% H: 7.56% C: -1.68%
conference

RenovoRx to Present at the 36th Annual ROTH Conference on March 19, 2024
Published: 2024-03-12 (Crawled : 15:00) - biospace.com/
RNXT | $1.23 0.82% 0.81% 20K

| -30.77% | O: -5.32% H: 6.87% C: 5.62%
conference

RenovoRx Highlights Key Leadership Promotions
Published: 2024-03-08 (Crawled : 00:20) - renovorx.com
RNXT | $1.23 0.82% 0.81% 20K

| Email alert Add to watchlist
key

RenovoRx CEO Issues Letter to Shareholders
Published: 2024-02-06 (Crawled : 14:00) - biospace.com/
RNXT | $1.23 0.82% 0.81% 20K

| -29.52% | O: 4.82% H: 0.0% C: -4.02%
ceo

RenovoRx Closes $6.1 Million Private Placement
Published: 2024-01-29 (Crawled : 15:00) - biospace.com/
RNXT | $1.23 0.82% 0.81% 20K

| 11.43% | O: 0.0% H: 36.81% C: 15.24%
million

RenovoRx Engages Oklahoma University (OU) Health as First Clinical Site in Preparation for the Pivotal Phase III CouGar Clinical Trial in Bile Duct Cancer
Published: 2023-12-21 (Crawled : 14:00) - biospace.com/
RNXT | $1.23 0.82% 0.81% 20K

| 64.79% | O: 2.68% H: 20.71% C: 16.56%
first health cancer trial

See all

Last 15 days Sec forms

File Id	Form	Published Date	Transaction Date	Direction	Code	Amount Transacted	Owned Amount
0001493152-24-009409	4	2024-03-08	2024-03-06	Buy	A	190000	190000
0001493152-24-005939	4	2024-02-13	2024-02-09	Buy	A	15000	15000